facebook twitter linkedin

This material was prepared by a third party towards Selvita S.A. with its registered office in Kraków (hereunder: “Selvita”). Within the scope which was not authorized by Selvita’s management board, the description of factual circumstances regarding the activities of Selvita, embodied in this material presents merely opinion of the third party, in particular with respect to presented opinions, predictions, appraisals and forecasts of the financial data and future activity of Selvita and its results.

Therefore, Selvita does not warrant consistency of this material with the actual and legal situation. Neither Selvita, members of its corporate bodies, employees nor its consultants shall bear any liability for validity of opinions, predictions, appraisals, forecasts and any other date embodied in this material as well as for consequences of actions of any reader made on a basis of this material, in particular for the investment decisions or any losses resulting from use of this material.

Readers of this material shall make its own assessment, whether opinions or forecasts embodied therein are credible and adequate, in particular taking into account their investment strategy and actual and legal situation. In particular they should consult it with their independent financial and investment advisors. None of the information presented in this material shall constitute investment, legal, accounting or tax advice or a statement that any investment strategy is accurate or adequate, considering the circumstances of the reader.

Furthermore date presented in this material shall not constitute an offer to sell or purchase any financial instruments nor an invite the make such offer. It shall not be also not deemed as a recommendation for investment in any financial instrument nor an advertisement of such instruments.



DISAGREE AGREE

  • Kraków, Poland - 7 December 2012 - Selvita announced today that it has obtained CIR accreditation from the French Ministry of Higher Education and Research for a three-year period of 2012-2014. The French Reseach and Development tax credit initiative ('Crédit d'Impôt Recherche', CIR) gives eligible research-based French companies, who are...
  • In the third quarter of 2012, Group Selvita SA revenues amounted to 4,811.9k PLN, while in the same period of 2011, revenues amounted to 3,885.4k PLN, thus the y-o-y revenue growth was 23.8%. Even a higher revenue growth - of 26.2% - Selvita Group recorded for the sum of the first three quarters of this year: from 9 566.5k PLN in 2011 to 12 070.2k...
  • BIO-Europe is Europe's largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry. The upcoming...
  •   In the second quarter of 2012, total revenues of the Selvita Group rose from 2,810.8 thousand PLN in the same period in 2011 to 4,045.5 thousand PLN. Achieving such revenue growth rate (43.9%) was possible thanks to larger value of the contracts and innovative projects co-financed by the European Union. Net sales amounted to 2,274.6...
  •   Kraków (Poland), 12 November 2012 - Selvita, Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS and oncology disorders, as well as provision of non-clinical research services, reported the most recent data from two of its oncology programs at the 24th EORTC-NCI-AACR Symposium...
  •   Selvita will participate in one of the greatest pharmaceutical events this year. ICSE | BioPh and InnoPack 2012, along with co-located events CPhI Worldwide for Pharmaceutical Ingredients and P-MEC Europefor Pharmaceutical Machinery, Equipment and Technology, are an unrivalled networking and business event for the global pharma community....
  • BioPharm America is where biotech industry partnerships get started. This partnering conference, taking place on 19-21 September 2012 in Boston, USA, offers ability to meet face-to-face with biotech and pharma executives and present your company to the most reputable audience from the industry. Equipped with the partneringONE partnering...
  • Kraków (Poland)/Espoo (Finland), 28 June 2012 - Selvita, a biotechnology company from Krakow, Poland (PL:SLV) announced today that its collaboration with Orion Corporation from Espoo, Finland (ORNBV) on SEL103 program, for the symptomatic treatment of Alzheimer's disease has reached the main research milestone and that the jointly discovered...
  • Selvita SA, the largest independent drug discovery company in Central Eastern Europe, published its financial results for the first quarter of 2012.In the Q1 2012, Selvita Group reached revenue of 3.212,7 k PLN, while in the analogous quarter in year 2011, revenue amounted to 2.856,5 k PLN, thus the revenue growth dynamics was at 12,5%. Achieving...
  •   Place: 23-24th May 2012, Brno, Czech Republic   Selvita will participate and exhibt in the 11th Central European Forum of Biotechnology and Innovative BioEconomy. The biggest and the most important international event for biotechnology in the region of Central Europe 23-24th May, Brno, Czech Republic.   Since the year 2000...
  •   Place: 18th-21st June 2012, Boston Convention & Exhibition Center, MA, USA   The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends...
  •     March 2, 2012, Krakow, Poland - Selvita, Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS and oncology disorders, as well as provision of non-clinical research services, announced today that data from two of its oncology programs is scheduled to be reported at the AACR...
  •   Krakow, 15 February 2012 - Selvita SA, the largest independent drug discovery company in Central Eastern Europe, published on February 14, 2012 financial results for the fourth quarter of 2011.During Q1-Q4 2011 Selvita Group reached net revenue of 9018,1k PLN, while in the same period in 2010, sales amounted to 8846,6k PLN. Achieving this...
  •   February 9, 2012, Kraków, Poland - Selvita, Polish, biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS, oncology and autoimmune disorders, announced today that data from two of its oncology programs is scheduled to be reported at the 3rd Cancer Targets and Therapeutics Conference,...
  • Place: 27th - 28th February 2012, Las Vegas, USA   The Oncology Partnering & Deal Making Conference is a partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as...
  •   On 27 January 2012, the Supervisory Board of Selvita S.A. made an appointment of new members to the Management Board of the company, namely Dr. Krzysztof Brzózka, Dr. Miłosz Gruca and Mr Sebastian Kwaśny, and recalled Dr. Nicolas Beuzen from his previous function.   As of 30 January 2012, Management Board includes following...
  • Place: 23 - 25 March 2012, Berlin, Germany   CPhI Conferences? 5th annual Strategies in Pharma Outsourcing conference has established itself as the market-leading forum for the pharmaceutical outsourcing community, allowing you to discover new partnership models and contracting strategies to enhance your pre-clinical, clinical and...
  • Place: 13th - 14th February 2012, New York, USAThe BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. It's mission is to support industry-wide success, and present a broad and unbiased view of investment opportunities.BIO One-on-One Partnering provides an...
  • Place: 5th-6th March, 2012, Zurich, Switzerland The 5th Annual European Life Sciences CEO Forum for Partnering & Investing is recognised as a leading international stage for those interested in investing in the Life Science and Biotech industries and is highly transactional. It draws together an exciting cross-section of...
  •   Location: 19th - 21st March 2012, Amsterdam, The Netherlands BIO-Europe is Europe's largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded...